Teva UK has launched its proprietary version of filgrastim, TevaGrastim, marking the company’s first biosimilar and a major addition to its hospitals portfolio.
TevaGrastim is licensed for a number of indications, the most common being the reduction of chemotherapy-induced neutropaenia. The licensed indications are the same as for the reference product Neupogen (filgrastim).
The product is available as a 30MIU pre-filled syringe and a 48MIU pre-filled syringe. Teva’s pre-filled syringe will also incorporate a needle guard to minimise the risk of needlestick injuries.
A biosimilar is defined as a similar biological medicinal product, and is also sometimes called a biogeneric.
Teva UK Limited is one of the UK’s leading pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. With over 500 product lines, it has the widest range of any UK generic pharmaceutical company, and has a number of respiratory products including the Qvar (beclometasone dipropionate) CFC-free inhaler.